MacroGenics, Inc. Share Price & Technical Analysis
MGNX · $4.53 (+6.84%)
Healthcare / Biotechnology
$4.53
+6.84%
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical tria…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
50% return in May, -41% avg return in past 3 year May month.
120% return in 2026, 0% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 13% | 5% | 45% | 7% | 50% | – | – | – | – | – | – | – | 120% |
| 25 | -9% | -14% | -48% | 31% | -18% | -14% | 33% | 20% | -6% | 0% | -6% | 7% | -24% |
| 24 | 51% | 24% | -19% | 1% | -72% | 2% | -10% | -5% | -3% | 16% | -3% | -11% | -29% |
| 23 | -15% | 5% | 18% | -3% | -32% | 13% | -11% | -2% | -2% | 11% | 55% | 17% | 54% |
| 22 | -22% | -24% | -5% | -18% | -51% | -14% | 3% | 29% | -12% | 42% | 23% | 2% | -50% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$228.80M
P/E ratio
—
52W high
$4.64
52W low
$1.19
Volume
11,04,365
Beta
1.08
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is MacroGenics, Inc. share price today?
- MacroGenics, Inc. (MGNX) last traded around $4.53 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MGNX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MGNX. Download the app for real-time alerts.
- How can I analyze MacroGenics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.